Pemphigus Erythematosus Medication
- Author: Rakesh Bharti, MD, MBBS; Chief Editor: William D James, MD more...
The goal of pharmacotherapy in pemphigus erythematosus is to reduce morbidity and to prevent complications.
Plasmapheresis and immunoadsorption have been shown to be effective in the treatment of pemphigus erythematosus. Plasmapheresis[23, 24, 25, 26] and, more recently, immunoadsorption,[27, 28, 29] are extracorporeal treatments that act rapidly on disease activity by lowering the load of the causative autoantibodies in the patient's circulation, causing a rebound of the plasma cell clone. During rebound, the plasma cells are more sensitive to chemotherapy.
In immunoadsorption, the immunoglobulins are selectively removed from the patient's plasma by adsorbing the antibodies to the matrix in a column of the immunoadsorption apparatus, after which the "cleansed" plasma is returned to the patient. Reportedly, immunoadsorption has higher efficacy and fewer adverse effects compared with plasmapheresis. In one German study, immunoadsorption was effective and safe in treating resistant and severe pemphigus. However, more studies are needed to support these data.
The mainstay of treatment of immunobullous diseases is steroids. Generally, high-dose steroids (ie, prednisolone, prednisone, methylprednisolone, dexamethasone), PO or IV, are effective in obtaining rapid disease control. However, high-dose and prolonged treatment with steroids often causes significant adverse effects. Screening and risk assessment of possible adverse effects (eg, diabetes, glaucoma, osteoporosis, blood pressure, history of GI bleeding) are required prior to and during treatment.
Concomitant calcium supplements and antacid drugs (eg, proton pump inhibitors) are recommended throughout therapy. A study of patients with pemphigus vulgaris showed intravenous pulse combined with low-dose oral steroid therapy to be effective and associated with fewer severe adverse effects than oral high-dose steroid therapy.
To reduce the adverse effects of systemic steroids, French researchers compared the efficacy and adverse effect profile of topical steroids with that of systemic steroids in the treatment of moderate-to-severe bullous pemphigoid. Topical steroids were more effective than oral therapy and were associated with far fewer severe complications. However, a 2003 report warns of the development of steroid-induced skin atrophy and striae after this regimen, and it has not been validated in other immunobullous diseases.
Prednisone is an immunosuppressant for the treatment of autoimmune disorders; it may decrease inflammation by reversing increased capillary permeability and suppressing PMN activity. It stabilizes lysosomal membranes and suppresses lymphocyte and antibody production.
These agents inhibit cell growth and proliferation and serve as steroid-sparing agents. Intravenous pulse cyclophosphamide (500 mg qd) has also been suggested as adjunctive therapy after plasmapheresis to prevent "rebound" (marked increase of antibodies compensating for the antibodies depleted by plasmapheresis).
High-dose immunoablative cyclophosphamide without stem cell rescue was effective in 2 patients with resistant pemphigus. However, considering the serious adverse effects of this high-dose regimen, it should be reserved for patients who are resistant to other treatments.[34, 35, 36]
Several regimens with cyclophosphamide have been described in the treatment of immunobullous disorders. Cyclophosphamide is a potent cytotoxic agent that can cause severe cytopenia and hemorrhagic cystitis (bladder inflammation).
Oral low-dose cyclophosphamide is usually used as a steroid-sparing agent.
Intravenous cyclophosphamide (500 mg qd for 1 d) plus low-dose oral (50 mg qd) has been combined with intravenous pulse dexamethasone (100 mg qd for 3 d) to achieve rapid disease control.
Intravenous pulse cyclophosphamide (500 mg qd) has also been suggested as adjunctive therapy after plasmapheresis to prevent "rebound" (marked increase of antibodies compensating for the antibodies depleted by plasmapheresis).
More recently, high-dose immunoablative cyclophosphamide without stem cell rescue was effective in 2 patients with resistant pemphigus. However, considering the serious adverse effects of this high-dose regimen, it should be reserved for patients who are resistant to other treatments.
More studies are needed to outline the risk of adverse effects vs benefits of this regimen.
Dapsone's anti-inflammatory mechanism of action differs from the antibacterial mechanism of action. Suppression of neutrophils by inhibiting the halide-myeloperoxidase system is the most likely mechanism of action for anti-inflammatory effects.
Dapsone is bactericidal and bacteriostatic against mycobacteria; its mechanism of action is similar to that of sulfonamides, where competitive antagonists of PABA prevent formation of folic acid, inhibiting bacterial growth.
These agents are effective in the treatment of autoimmune diseases. See Glied and Rico and Tan et al for references regarding adverse effects (eg, abnormal LFT results) related to thiopurine-methyltransferase (TPMT).
Also see the clinical guideline summary from the British Association of Dermatologists, Guidelines for prescribing azathioprine in dermatology.
Among the slowly acting adjuvant therapies, azathioprine is a useful and safe steroid-sparing agent, provided TPMT assay is performed prior to treatment. TPMT is an enzyme that converts azathioprine into its inactive metabolites.
If TPMT is lacking or present in a much lower concentration, patient is at high risk for bone marrow suppression and thus anemia, thrombocytopenia, and leukopenia. Therefore, analysis of TPMT levels is recommended before starting treatment.
Other adverse effects (eg, abnormal LFT results) are not reflected by this enzyme level.
IVIGs have proven beneficial in achieving rapid disease control in patients with immunobullous diseases.[40, 41, 42, 43, 44, 45]
Immune globulin intravenous consists of IgG collected from a pool of thousands of blood donors (virus-free), thus providing a wide range of immunologically different IgG. Theoretically, they bind and neutralize pathogenic autoantibodies.
It is administered IV, with each cycle lasting 3-5 days, at a dose of 1-2 g/kg/cycle. Several cycles are usually required.
Cost and availability limit its use. IVIG is expensive. It is generally used in resistant and severe bullous diseases in addition to immunosuppressive therapy or as monotherapy in patients with contraindications for immunosuppressive drugs.
Anti-inflammatory agents (eg, dapsone, gold, tetracyclines) are also being used to treat certain immunobullous disorders. However, they are generally used in patients with mild-to-moderate disease, with the exception of those with dermatitis herpetiformis and linear IgA disease, in whom dapsone is still first-line treatment. Dapsone can be started after glucose-6-P-dehydrogenase screening. Low levels are associated with a high risk of methemoglobinemia. When using tetracyclines, some authors have reported minocycline-induced pigmentation in patients with pemphigus and pemphigoid, with a prevalence that appears to be much higher than in persons with acne or rheumatoid arthritis.
Rituximab targets a cell-specific protein and may represent a promising novel therapeutic option for refractory immunobullous diseases.[47, 48, 49, 50]
Rituximab is a monoclonal anti-CD20 antibody (CD20 is a protein on the surface of lymphocytes), reported to be effective in treating resistant pemphigus foliaceous and vulgaris. It may deplete B lymphocytes (antibody-producing cells) and rapidly removes desmoglein antibodies (antibodies causing pemphigus) from circulation.
Pérez-Pérez ME, Avalos-Díaz E, Herrera-Esparza R. Autoantibodies in senear-usher syndrome: cross-reactivity or multiple autoimmunity?. Autoimmune Dis. 2012. 2012:296214. [Medline].
Brenner S, Mashiah J, Tamir E, et al. PEMPHIGUS. An Acronym for a Disease with Multiple Causes. The International Pemphigus Foundation. Available at http://www.pemphigus.org/pemphigus-an-acronym-for-a-disease-with-multiple-causes-2/. Accessed: May 29, 2005.
Oktarina DA, Poot AM, Kramer D, Diercks GF, Jonkman MF, Pas HH. The IgG "Lupus-Band" Deposition Pattern of Pemphigus Erythematosus: Association With the Desmoglein 1 Ectodomain as Revealed by 3 Cases. Arch Dermatol. 2012 Jul 16. 1-6. [Medline].
Singh S. Evidence-based treatments for pemphigus vulgaris, pemphigus foliaceus, and bullous pemphigoid: a systematic review. Indian J Dermatol Venereol Leprol. 2011 Jul-Aug. 77(4):456-69. [Medline].
Griffies JD, Mendelsohn CL, Rosenkrantz WS, et al. Topical 0.1% tacrolimus for the treatment of discoid lupus erythematosus and pemphigus erythematosus in dogs. J Am Anim Hosp Assoc. 2004 Jan-Feb. 40(1):29-41. [Medline].
Basset N, Guillot B, Michel B, Meynadier J, Guilhou JJ. Dapsone as initial treatment in superficial pemphigus. Report of nine cases. Arch Dermatol. 1987 Jun. 123(6):783-5. [Medline].
Piamphongsant T. Pemphigus controlled by dapsone. Br J Dermatol. 1976 Jun. 94(6):681-6. [Medline].
Chaffins ML, Collison D, Fivenson DP. Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases. J Am Acad Dermatol. 1993 Jun. 28(6):998-1000. [Medline].
Ahmed AR, Hombal SM. Cyclophosphamide (Cytoxan). A review on relevant pharmacology and clinical uses. J Am Acad Dermatol. 1984 Dec. 11(6):1115-26. [Medline].
Pasricha JS, Sood VD, Minocha Y. Treatment of pemphigus with cyclophosphamide. Br J Dermatol. 1975 Nov. 93(5):573-6. [Medline].
Heilborn JD, Stahle-Backdahl M, Albertioni F, Vassilaki I, Peterson C, Stephansson E. Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid. J Am Acad Dermatol. 1999 May. 40(5 Pt 1):741-9. [Medline].
Tan-Lim R, Bystryn JC. Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies. J Am Acad Dermatol. 1990 Jan. 22(1):35-40. [Medline].
Enk AH, Knop J. Mycophenolate is effective in the treatment of pemphigus vulgaris. Arch Dermatol. 1999 Jan. 135(1):54-6. [Medline].
Kaur S, Kanwar AJ. Dexamethasone-cyclophosphamide pulse therapy in pemphigus. Int J Dermatol. 1990 Jun. 29(5):371-4. [Medline].
Pasricha JS, Gupta R. Pulse therapy with dexamethasone-cyclophosphamide in pemphigus. Indian J Dermatol Venereol Leprol. 1984. 50:199-203.
Pasricha JS, Khaitan BK, Raman RS, Chandra M. Dexamethasone-cyclophosphamide pulse therapy for pemphigus. Int J Dermatol. 1995 Dec. 34(12):875-82. [Medline].
Pasricha JS, Thanzama J, Khan UK. Intermittent high-dose dexamethasone-cyclophosphamide therapy for pemphigus. Br J Dermatol. 1988 Jul. 119(1):73-7. [Medline].
Kandan S, Thappa DM. Outcome of dexamethasone-cyclophosphamide pulse therapy in pemphigus: a case series. Indian J Dermatol Venereol Leprol. 2009 Jul-Aug. 75(4):373-8. [Medline].
Pasricha JS. Current regimen of pulse therapy for pemphigus: minor modifications, improved results. Indian J Dermatol Venereol Leprol. 2008 May-Jun. 74(3):217-21. [Medline].
Ramam M. Prolonged antimicrobial and oral cyclophosphamide therapy in pemphigus: need for caution. Indian J Dermatol Venereol Leprol. 2009 Jan-Feb. 75(1):85. [Medline].
Egan CA, Meadows KP, Zone JJ. Plasmapheresis as a steroid saving procedure in bullous pemphigoid. Int J Dermatol. 2000 Mar. 39(3):230-5. [Medline].
Furue M, Iwata M, Yoon HI, et al. Epidermolysis bullosa acquisita: clinical response to plasma exchange therapy and circulating anti-basement membrane zone antibody titer. J Am Acad Dermatol. 1986 May. 14(5 Pt 2):873-8. [Medline].
Turner MS, Sutton D, Sauder DN. The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris. J Am Acad Dermatol. 2000 Dec. 43(6):1058-64. [Medline].
Bystryn JC. Plasmapheresis therapy of pemphigus. Arch Dermatol. 1988 Nov. 124(11):1702-4. [Medline].
Matic G, Bosch T, Ramlow W. Background and indications for protein A-based extracorporeal immunoadsorption. Ther Apher. 2001 Oct. 5(5):394-403. [Medline].
Ogata K, Yasuda K, Matsushita M, Kodama H. Successful treatment of adolescent pemphigus vulgaris by immunoadsorption method. J Dermatol. 1999 Apr. 26(4):236-9. [Medline].
Schneider KM. Plasmapheresis and immunoadsorption: different techniques and their current role in medical therapy. Kidney Int Suppl. 1998 Feb. 64:S61-5. [Medline].
Schmidt E, Klinker E, Opitz A, et al. Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus. Br J Dermatol. 2003 Jun. 148(6):1222-9. [Medline].
Femiano F, Gombos F, Scully C. Pemphigus vulgaris with oral involvement: evaluation of two different systemic corticosteroid therapeutic protocols. J Eur Acad Dermatol Venereol. 2002 Jul. 16(4):353-6. [Medline].
Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002 Jan 31. 346(5):321-7. [Medline].
Hull CM, McKenna JK, Zone JJ. Topical corticosteroids and bullous pemphigoid. Arch Dermatol. 2003 Feb. 139(2):225-6. [Medline].
Cohen MA, Cohen JJ, Kerdel FA. Immunoablative high-dose cyclophosphamide without stem cell rescue in pemphigus foliaceus. Int J Dermatol. 2002 Jun. 41(6):340-4. [Medline].
Hayag MV, Cohen JA, Kerdel FA. Immunoablative high-dose cyclophosphamide without stem cell rescue in a patient with pemphigus vulgaris. J Am Acad Dermatol. 2000 Dec. 43(6):1065-9. [Medline].
Nousari HC, Brodsky RA, Jones RJ, Grever MR, Anhalt GJ. Immunoablative high-dose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus: report of a case and review of this new therapy for severe autoimmune disease. J Am Acad Dermatol. 1999 May. 40(5 Pt 1):750-4. [Medline].
Glied M, Rico MJ. Treatment of autoimmune blistering diseases. Dermatol Clin. 1999 Apr. 17(2):431-40, x. [Medline].
Tan BB, Lear JT, Gawkrodger DJ, English JS. Azathioprine in dermatology: a survey of current practice in the U.K. Br J Dermatol. 1997 Mar. 136(3):351-5. [Medline].
[Guideline] Anstey AV, Wakelin S, Reynolds NJ. Guidelines for prescribing azathioprine in dermatology. Br J Dermatol. 2004 Dec. 151(6):1123-32. [Medline].
Ahmed AR, Colon JE. Comparison between intravenous immunoglobulin and conventional immunosuppressive therapy regimens in patients with severe oral pemphigoid: effects on disease progression in patients nonresponsive to dapsone therapy. Arch Dermatol. 2001 Sep. 137(9):1181-9. [Medline].
Ahmed AR. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol. 2001 Dec. 45(6):825-35. [Medline].
Ahmed AR, Sami N. Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional therapy. J Am Acad Dermatol. 2002 Jan. 46(1):42-9. [Medline].
Gourgiotou K, Exadaktylou D, Aroni K, et al. Epidermolysis bullosa acquisita: treatment with intravenous immunoglobulins. J Eur Acad Dermatol Venereol. 2002 Jan. 16(1):77-80. [Medline].
Leverkus M, Georgi M, Nie Z, Hashimoto T, Brocker EB, Zillikens D. Cicatricial pemphigoid with circulating IgA and IgG autoantibodies to the central portion of the BP180 ectodomain: beneficial effect of adjuvant therapy with high-dose intravenous immunoglobulin. J Am Acad Dermatol. 2002 Jan. 46(1):116-22. [Medline].
Sami N, Qureshi A, Ahmed AR. Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus. Eur J Dermatol. 2002 Mar-Apr. 12(2):174-8. [Medline].
Ozog DM, Gogstetter DS, Scott G, Gaspari AA. Minocycline-induced hyperpigmentation in patients with pemphigus and pemphigoid. Arch Dermatol. 2000 Sep. 136(9):1133-8. [Medline].
Borradori L, Lombardi T, Samson J, Girardet C, Saurat JH, Hugli A. Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol. 2001 Mar. 137(3):269-72. [Medline].
Goebeler M, Herzog S, Brocker EB, Zillikens D. Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab. Br J Dermatol. 2003 Oct. 149(4):899-901. [Medline].
Mrowietz U. Treatment targeted to cell surface epitopes. Clin Exp Dermatol. 2002 Oct. 27(7):591-6. [Medline].
Salopek TG, Logsetty S, Tredget EE. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol. 2002 Nov. 47(5):785-8. [Medline].